Welcome to our dedicated page for Callan JMB SEC filings (Ticker: CJMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Callan JMB Inc. filings document the public-company record of a Nevada corporation operating in healthcare logistics, cold-chain fulfillment, emergency preparedness support and pharmaceutical supply-chain services. The company’s Form 8-K reports furnish operating results, business updates, Regulation FD investor materials, material agreements and amendments to common stock purchase arrangements.
Registration statements describe the company’s securities offering, business disclosures, capital structure and risk factors. Proxy materials cover annual-meeting procedures, stockholder voting matters and governance. Recent current reports also document Nasdaq continued-listing compliance matters, including disclosures related to the stockholders’ equity standard for The Nasdaq Capital Market.
Callan JMB Inc. has received a Nasdaq notice that its common stock no longer meets the $1.00 minimum bid price requirement, based on 30 consecutive business days below that level. The stock continues to trade on the Nasdaq Capital Market under the symbol CJMB.
The company has an initial 180-day compliance period, until December 28, 2026, to regain compliance by achieving at least $1.00 per share for a minimum of ten consecutive business days, or longer if Nasdaq requires. If still noncompliant, a second 180-day period may be available, potentially involving a reverse stock split.
If compliance is not regained within the allowed periods, Nasdaq may initiate delisting, which the company could appeal to a Nasdaq Hearings Panel. Callan JMB states it will actively monitor its share price and consider options, including a reverse split, but there is no assurance it will maintain its listing.
Callan JMB Inc. reports the resignation of Executive Vice President and director Eric Kash, effective June 5, 2026. The company states his resignation was not due to any disagreement over its operations, policies, or practices.
Under a Settlement, Waiver and Release Agreement, Callan JMB will pay Mr. Kash $125,000 in severance in three monthly installments of $41,666.67, plus accrued unused vacation. He retains 187,500 vested stock options, which remain exercisable for their full 10-year term instead of a shorter post-termination window.
The agreement mutually releases claims between the parties, terminates his October 2024 employment agreement and amendment, and includes confidentiality and non-disparagement provisions. The company also notes forward-looking plans to submit a proposal to regain compliance with Nasdaq’s Stockholders’ Equity Requirement within 45 calendar days.
CALLAN JMB INC. director Gerald Dial reported two equity transactions. He made an open-market purchase of 10,000 shares of Common Stock at $0.762 per share, bringing his direct holdings to 12,000 shares. He also received a grant of options covering 25,000 shares of Common Stock that were granted on the first day of the company’s Initial Public Offering. According to the grant terms, the option vests on February 4, 2026 and expires on February 4, 2035, aligning the award with longer‑term company performance.
Callan JMB Inc. entered into an at-the-market Sales Agreement with Alexander Capital, L.P. allowing the company to offer and sell, from time to time, shares of common stock with an aggregate offering price of up to $5,000,000.
Sales will be made as “at the market offerings” under Rule 415, primarily through the Nasdaq Capital Market, and Alexander Capital will act as sales agent on a commercially reasonable efforts basis. Callan JMB will pay a 3.0% commission on gross proceeds, plus capped expense reimbursements, and plans to use net proceeds for working capital and general corporate purposes.
Callan JMB Inc. filed a shelf registration to offer up to $200,000,000 of securities and a related prospectus supplement for an at-the-market facility to sell up to $5,000,000 of common stock through Alexander Capital, L.P. under an ATM Agreement dated May 26, 2026. The company reported 5,646,118 shares outstanding and a public float of approximately $3,394,649 based on a 60-day high of $1.33 per share; the last reported sale price on Nasdaq was $0.78 per share on May 22, 2026.
Callan JMB Inc. reported a weaker first quarter of 2026 with revenue of $1,106,143, down 24% from the prior year, as a key government contract was not renewed and non-government sales declined. Gross profit fell to $427,235, while selling, general and administrative expenses rose 15% to $2,128,423, driven by higher payroll, new office rent, consulting and public-company costs.
The company’s net loss widened to $3,215,054 (loss of $0.59 per share) compared with $1,240,590 a year earlier, reflecting both operating losses and $1,177,223 of ELOC-related transaction expenses plus a $338,229 loss from changes in the fair value of its ELOC derivative liability.
At March 31, 2026, cash stood at $1,415,566 and stockholders’ equity was $1,599,533, below the $2,500,000 minimum required by Nasdaq. After quarter-end, Nasdaq notified the company of this equity deficiency. Management highlights access to an Equity Line of Credit with $23.45M remaining availability and ongoing support from its CEO as key liquidity sources, and believes its plans alleviate substantial doubt about continuing as a going concern over the next twelve months.
Callan JMB Inc disclosure: Bard Associates, Inc. amended a Schedule 13G/A to report beneficial ownership of 239,266 shares of Common Stock (CUSIP 131100109), representing 4.3% of the class. The filing shows shared dispositive power over those shares; voting power is reported as zero.
Callan JMB Inc. received a Nasdaq notice that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2,500,000 in stockholders’ equity to remain on The Nasdaq Capital Market. The company has 45 days, until May 22, 2026, to submit a plan to regain compliance and, if Nasdaq accepts the plan, may receive up to 180 days from the notice date, until October 4, 2026, to demonstrate compliance. Trading of its common stock under the symbol CJMB continues for now, but there is no assurance the plan will be accepted or that compliance will be restored.
Callan JMB Inc., a Nevada-based cold chain logistics and fulfillment company serving the life sciences industry, reports its annual business results for the year ended December 31, 2025. The company posted a net loss of $7,966,366 and had an accumulated deficit of $10,260,014 as of year end.
Callan JMB provides temperature-controlled packaging, emergency response logistics, and remote monitoring through its Ship2Q and Sentry platforms, targeting applications such as cell therapies, vaccines, diagnostics and other biologics. Its business is capital intensive and operates under a rent-to-rent warehouse model, which requires significant upfront investment in leased and renovated facilities.
The company highlights high customer concentration, with its top three customers contributing about 79% of 2025 revenue, and notes revenue pressure from one major customer temporarily suspending orders and another significantly reducing operations. As of March 25, 2026, Callan JMB had 5,627,368 common shares outstanding and employed 20 people.